Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 7, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

July 31, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Belantamab mafodotin

"Dose of 2.5 mg/kg/every 8 weeks on day 1, intravenously, Induction: three induction cycles with belantamab mafodotin in combination with VRd.~Consolidation: one cycle after 90 days of transplantation with belantamab mafodotin in combination with VRd.~Maintenance: belantamab mafodotin in combination with lenalidomide until disease progression, patients withdrawal, death or up to two years, whichever occurs first"

DRUG

Bortezomib

Dose of 1.3 mg/m2, on days: 1, 4, 8 and 11 of every 28-day cycle. Subcutaneous administration Induction: 6 cycles Consolidation: 2 cycles

DRUG

Lenalidomide

Dose of 25 mg/day on days 1-21 of every 28-day cycle. Oral administration. Induction: 6 cycles Consolidation: 2 cycles Maintenance: 10 mg/day on days 1-21 continuously (may increase up to 15 mg/day) until disease progression, patients withdrawal, death, whichever occurs first

DRUG

Dexamethasone

Dose of 20 mg on days: 1, 2, 4, 5, 8, 9, 11 and 12 of every 28-day cycle. Oral administration Induction: 6 cycles Consolidation: 2 cycles

PROCEDURE

Autologous stem cell transplant (ASCT)

High-dose melphalan (200 mg/m2) and ASCT will be performed as per routine practice

Trial Locations (18)

15706

RECRUITING

Complejo Universitario Hospitalario de Santiago, Santiago de Compostela

28007

RECRUITING

Hospital Gregorio Marañon, Madrid

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

30008

RECRUITING

Hospital General Universitario Morales Meseguer, Murcia

31008

WITHDRAWN

Clinica Universidad Navarra (CUN), Pamplona

33394

RECRUITING

Hospital de Cabueñes, Gijón

37007

RECRUITING

Hospital Universitario de Salamanca, Salamanca

38320

NOT_YET_RECRUITING

Hospital Universitario de Canarias, San Cristóbal de La Laguna

39008

RECRUITING

Hospital Universitario Marqués de Valdecilla, Santander

41013

WITHDRAWN

Complejo Hospitalario Regional Virgen del Rocío, Seville

46026

RECRUITING

Hospital Universitario y Policlínico de la Fe, Valencia

07198

RECRUITING

Hospital Son Llatzer, Palma de Mallorca

08916

WITHDRAWN

Institut Catala d'Oncologia (ICO) Badalona, Badalona

08036

NOT_YET_RECRUITING

Hospital Clínic I Provincial de Barcelona, Barcelona

08908

WITHDRAWN

Institut Catala d'Oncologia (ICO) Hospitalet, L'Hospitalet de Llobregat

Unknown

RECRUITING

Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria

RECRUITING

Hospital Infanta Leonor, Madrid

RECRUITING

Hospital Virgen de la Arrixaca, Murcia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

PETHEMA Foundation

OTHER

NCT04802356 - Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | Biotech Hunter | Biotech Hunter